Emerging Roles of Antidiabetic Drugs beyond Glucose Control: Beneficial Effects on Hepatitis and Hepatocellular Carcinoma - Abstract
Insulin resistance and hyperglycemia in type 2 diabetes mellitus (T2DM) are both correlated with hepatitis and hepatocyte carcinoma. Thiazolidinediones and biguanides, belong to insulin sensitizers, are front-line antidiabetic drugs. DPP-4 inhibitors, a member of incretin-based products, are novel target in the treatment of T2DM. These drugs are widely used to treat T2DM by improving insulin actions and regulating glucose homeostasis. In addition to their antidiabetic roles, increased incidences have been recently reported to treat hepatitis and hepatocellular carcinoma. These underappreciated effects indicate that antidiabetic agents could be re-purposed therapeutic strategies for treatments of liver diseases in patients with diabetes.